A new fallen angel that I think more aggressive investors should consider is Crispr Therapeutics (CRSP), suggests Jim Powell, editor of Global Changes & Opportunities Report.

This is a company that pioneered the gene editing technology that is opening the door to conquering many diseases caused by errors in human DNA. There may be genetic cures for cancer, cystic fibrosis, sickle cell disease, heart disease, diabetes, and AIDS – to name only a few.

For safety reasons, the company is focused on changing the genes of individual patients, not making modifications to hereditary DNA that could be passed onto future generations.

As with most promising biotech companies, investors bid their prices up for CRSP based upon its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. When the company becomes profitable, investors will come flocking back. It's a familiar pattern.

That's what happened with Genentech (now part of Roche Holdings), Amgen, (AMGN), Gilead Sciences (GILD), Biogen (BIIG), Novavax (NVAX) and several other industry leaders.

A modest investment in any of them during their volatile past would have been like winning a lottery a few years later. I think the same is likely to be true of Crispr Technologies the acknowledged leader in the promising field of gene editing and repair.

The technology created by Crispr should lead to many important medical advances. Vertex Pharmaceuticals (VRTX) recently made a $900 million pledge to Crispr to help create a genetic cure for anemia.

We are double dippers with Crispr Therapeutics. I first recommended the company in March 2019 when it was $39.97. It is now over $100.

I think we will see more profits come our way from CRSP. The stock recently rose to $165.70 when investors realized that gene editing had the potential to protect people against deadly viruses. I think Crispr will revisit that mark and go beyond it.